Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Oz Harmanli

Urogynecology and Reconstructive Pelvic Surgery New Haven, CT Medical Doctor

NPI 1982791505 CMS profile 316707

800 Howard Ave, 3Rd Floor, New Haven, CT 06519

Open in the dashboard

General payments

$8,651

21 records reported · program years 2019–2025

Research payments

$21,521

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$277,009 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Oz Harmanli of New Haven, CT is reported in the CMS Open Payments database as having received $8,651 across 21 general payments and $21,521 in research payments paid to them. Separately, studies naming them as principal investigator received $277,009 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31 1
2025 Research $7,500 2
2024 General $291 2
2023 General $4,311 7
2022 General $1,919 9
2021 General $1,875 1
2021 Research $6,824 2
2019 General $225 1
2019 Research $7,197 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Oz Harmanli
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Oz Harmanli were reported at $31. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Oz Harmanli Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $225 $358 $132–$1,270 $163
2020 $0 $198 $86–$642 $114
2021 $1,875 $361 $118–$1,182 $132
2022 $1,919 $410 $128–$1,175 $149
2023 $4,311 $434 $152–$1,344 $160
2024 $291 $494 $193–$1,331 $164
2025 $31 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Applied Medical Resources Corporation $3,679 9 payments
  2. Boston Scientific Corporation $2,495 6 payments
  3. Caldera Medical, Inc $2,020 3 payments
  4. CooperSurgical, Inc. $225 1 payment
  5. Coloplast Corp $122 1 payment
  6. Axonics Modulation Technologies, Inc. $110 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,975 6 payments
  2. Travel and Lodging $2,732 3 payments
  3. Food and Beverage $945 12 payments
Products named General payments · program years 2019–2025
  1. Desara $2,020 3 payments
  2. CAPIO $1,875 1 payment
  3. GelPOINT V-Path Specialty Access $847 4 payments
  4. GelPOINT V-Path Specialty Access $683 1 payment
  5. Solyx SIS System $227 3 payments
  6. Advantage System $225 1 payment
  7. GYN Office Instrumental $225 1 payment
  8. Altis $122 1 payment
  9. Bulkamid $110 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $21,521 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

56

Median for Obstetrics & Gynecology: 65

Drug cost

$9,421

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

28.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 16 $7,154
Estradiol Generic 40 $2,266

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$49,267

Medicare's payments for the services billed

Medicare patients

124

Average age 74

Services billed

341

124 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 56%
Osteoporosis 31%
Depression 25%
Cancer 24%
Diabetes 15%
Ischemic heart disease 15%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record